English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 3/5 criteria met. Data as of 01/11/2026.
- ❌ Price trend failed
- ✅ Growth passed
- ✅ Debt passed
- ✅ P/E passed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: 28.67%
Price change 2019 → 2020: 154.35%
Price change 2020 → 2021: 32.05%
Price change 2021 → 2022: -52.91%
Price change 2022 → 2023: -37.11%
Price change 2023 → 2024: -8.74%
Price change 2024 → 2025: 47.31%
Price change 2025 → 2026: -14.63%
Price change 2026 (year to date): -16.67%
Financial growth
Revenue CAGR (8 years): 10.02%
Earnings CAGR (8 years): 12.95%
Growth status: positive trend (>1%/yr) in revenue and earnings.
Debt
Debt-to-equity ratio: 0.10
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 10.08
P/E < 25.0 (maximum threshold).
Correction (6 months)
Current correction: 31.82% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="AJ91.DE" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| DocCheck AG | 10.1 | 0.10 | +8.9 % | 🔒 |
| Klea Holding | 15.8 | 0.20 | +5.2 % | – |
| Fermentalg | – | 0.20 | +38.5 % | – |
| Adocia S.A. | – | 5.97 | +18.8 % | – |
| Cellectis S.A. | – | 1.20 | +8.9 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by DocCheck AG over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 70.3 m | 10.3 m | 14.6 % | n/a |
| 2021 | 95.8 m | 12.7 m | 13.3 % | +36.2 % |
| 2022 | 67.9 m | 7.0 m | 10.3 % | -29.1 % |
| 2023 | 59.5 m | 2.5 m | 4.2 % | -12.3 % |
| 2024 | 60.0 m | 5.9 m | 9.8 % | +0.7 % |
| 2025 | 61.7 m | 5.9 m | 9.6 % | +2.8 % |
Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.
Accounts and financial health
Balance sheet and cash flow published by DocCheck AG over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 21.5 m | 15.7 m | 17.5 m | 21.0 m | 18.5 m |
| Total Debt | 7.0 m | 7.1 m | 5.9 m | 5.0 m | 4.2 m |
| Net Debt | -11.2 m | -6.3 m | -8.5 m | -12.0 m | -10.3 m |
| Equity | 37.3 m | 38.6 m | 37.3 m | 40.1 m | 41.6 m |
| Total assets | 60.3 m | 63.3 m | 56.1 m | 60.9 m | 55.7 m |
| Operating cash flow | 10.9 m | 5.9 m | 7.5 m | 7.6 m | 6.1 m |
| Investments (capex) | 4.0 m | 6.4 m | 1.9 m | 1.1 m | 3.7 m |
| Free cash-flow | 6.9 m | -557,911 | 5.6 m | 6.8 m | 2.6 m |
| Share buybacks | 5.0 m | 0 | 0 | 0 | 0 |
| Dividends paid | 5.0 m | 5.0 m | 3.8 m | 2.5 m | 3.8 m |
Amounts in EUR, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.
Valuation and competitors
DocCheck AG compared with its sector on the same exchange and with its main competitors.
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 09/11/2026. Competitors: comparable companies named by the data provider.
Dividends and earnings
DocCheck AG: dividend history, last distributions, stock splits and earnings releases.
Annual dividend per share (EUR), adjusted for splits. Light bar: current year, incomplete. Red bar: lower than the previous year.
Latest ex-dividend dates
| Ex-dividend | Amount | Payment |
|---|---|---|
| 29/05/2026 | 1.00 EUR | 02/06/2026 |
| 29/05/2025 | 0.750 EUR | 02/06/2025 |
| 30/05/2024 | 0.500 EUR | 03/06/2024 |
| 01/06/2023 | 0.750 EUR | 05/06/2023 |
| 01/06/2022 | 1.00 EUR | 03/06/2022 |
| 31/05/2021 | 1.00 EUR | 02/06/2021 |
| 01/06/2020 | 0.100 EUR | 04/06/2020 |
| 30/05/2019 | 0.400 EUR | 04/06/2019 |
Factual data: ex-dividend history and earnings calendar, as of 05/11/2026. A past dividend does not guarantee the next one.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about DocCheck AG
What is the DocCheck AG share price?
Latest recorded price: 10.30 EUR on 06/11/2026, for a market cap of 58.3 m USD.
What is the revenue of DocCheck AG?
61.7 m USD for fiscal year 2025, with net income of 5.9 m USD (net margin 9.6 %).
Does DocCheck AG pay a dividend?
Yes. Latest dividend: 1.00 EUR per share, ex-dividend on 29/05/2026. Over 12 months: 1.00 EUR. Yield on the latest known price: 6.1 %.
What is the P/E ratio of DocCheck AG?
Trailing 12-month P/E of 11.2, against 31.2 for the sector median on the same exchange (10-year median: 26.9).
Is DocCheck AG stock eligible for the French PEA?
Likely: the company is headquartered in the European Union or the European Economic Area (ISIN DE000A1A6WE6) and the stock is listed on a European exchange. The institution holding the PEA confirms eligibility.
How many employees does DocCheck AG have?
373 full-time employees according to the latest published profile.
Who runs DocCheck AG?
Frank Nicolas Antwerpes is the company's chief executive.